Cohort Event Monitoring Study of Pyramax®
Phase IIIb/IV Cohort Event Monitoring Study To Evaluate, In Real Life Setting, The Safety And Tolerability In Malaria Patients Of The Fixed-Dose Artemisinin-Based Combination Therapy Pyramax®
Sponsor: Medicines for Malaria Venture
Listed as NCT03201770, this PHASE4 trial focuses on Malaria,Falciparum and remains completed. Sponsored by Medicines for Malaria Venture, it has been updated 9 times since 2017, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jul 2019 — Jan 2021 [monthly]
Completed PHASE4
Status: Recruiting → Completed
▶ Show 4 earlier versions
-
Jun 2018 — Jul 2019 [monthly]
Recruiting PHASE4
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE4
-
Dec 2017 — Feb 2018 [monthly]
Recruiting PHASE4
-
Jul 2017 — Dec 2017 [monthly]
Recruiting PHASE4
First recorded
Jun 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Medicines for Malaria Venture
- Shin Poong Pharmaceutical Co. Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .